CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
The closing of the Offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $5 million,
Hosted on MSN5h
Cero Therapeutics prices $5M at-the-market offeringCERo Therapeutics (CERO) announced the pricing of its “reasonable best efforts” public offering with participation from a ...
Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” ...
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. Week of Feb. 3 Titan ...
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...
Facebook (FB), now Meta Platforms Inc. (META), went public with its initial public offering (IPO) on May 18, 2012. The popular social networking company had one of the largest and most ...
Investing.com -- Immunome, Inc. (NASDAQ:IMNM) shares fell sharply by 9.6% following the announcement of the pricing of its upsized public offering of common stock. The biotechnology company ...
In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback